A federal appeals court affirmed July 16 a district court’s decision rejecting a researcher’s claim that she contributed to the development of a GenSpera Inc. cancer treatment (GenSpera, Inc. v. Mhakaaffirmed).
Annastasiah Mudiwa Mhaka filed litigation in 2012 in the U.S. District Court for the District of Maryland, alleging that she conceived of and ultimately synthesized a critical compound claimed in two U.S. patents. Mhaka sought to be named as an inventor on the patents and filed tort claims of conversion, constructive fraud and unjust enrichment against biotechnology company GenSpera and the two named inventors.
On Sept. 2, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.